Duramorphmorphine

According to the FDA label: Opium tincture is useful for the treatment of diarrhea.

66,232 adverse event reports submitted to the FDA (1999–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Duramorph in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Duramorph adverse event reports by reporter sex
SexReports
Female34,026
Male26,076
Unknown219

By Age Group

View age group data as a table
Duramorph adverse event reports by reporter age group
Age groupReports
0-171,164
18-343,389
35-496,947
50-6411,865
65-747,189
75+5,376

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Duramorph. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Duramorph adverse event reports by reported outcome
OutcomeReports
Other Serious36,150
Hospitalization16,090
Non-Serious15,254
Death11,748
Disability3,343
Life-Threatening2,817

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Duramorph. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Duramorph adverse event reports by year
YearReports
19993
20041,244
20051,048
2006952
2007530
2008649
2009697
2010892
20111,191
20121,840
20131,474
20141,864
20152,362
20162,934
20172,716
20185,582
20194,362
20203,821
20217,864
20228,453
20238,189
20243,556
20253,327
2026 (partial)682

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Duramorph

In FDA adverse event reports that mention Duramorph, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026